We have demonstrated that ctDNA assessment could predict the therapy response in NKTCL, and the highest mutation frequencies were in KMT2D, APC, ATM, ASXL3, JAK3, SETD2, TP53, NOTCH1. Our results could define the optimal strategy for patient follow-up. This evidence concerns the gene APC and extranodal nasal NK/T cell lymphoma.